Cargando…

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) cell therapies have been claimed to be curative in responsive patients. Nonetheless, response rates can vary according to different characteristics, and these therapies are associated with important adverse events such as cytokine release syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiz, Luis Carlos, Leache, Leire, Gutiérrez-Valencia, Marta, Erviti, Juan, Rojas Reyes, María Ximena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150428/
https://www.ncbi.nlm.nih.gov/pubmed/37138698
http://dx.doi.org/10.1177/20406207231168211
_version_ 1785035358354800640
author Saiz, Luis Carlos
Leache, Leire
Gutiérrez-Valencia, Marta
Erviti, Juan
Rojas Reyes, María Ximena
author_facet Saiz, Luis Carlos
Leache, Leire
Gutiérrez-Valencia, Marta
Erviti, Juan
Rojas Reyes, María Ximena
author_sort Saiz, Luis Carlos
collection PubMed
description BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) cell therapies have been claimed to be curative in responsive patients. Nonetheless, response rates can vary according to different characteristics, and these therapies are associated with important adverse events such as cytokine release syndrome, neurologic adverse events, and B-cell aplasia. OBJECTIVES: This living systematic review aims to provide a timely, rigorous, and continuously updated synthesis of the evidence available on the role of CAR-T therapy for the treatment of patients with hematologic malignancies. DESIGN: A systematic review with meta-analysis of randomized controlled trials (RCTs) and comparative non-randomized studies of interventions (NRSI), evaluating the effect of CAR-T therapy versus other active treatments, hematopoietic stem cell transplantation, standard of care (SoC) or any other intervention, was performed in patients with hematologic malignancies. The primary outcome is overall survival (OS). Certainty of the evidence was determined using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. DATA SOURCES AND METHODS: Searches were performed in the Epistemonikos database, which collates information from multiple sources to identify systematic reviews and their included primary studies, including Cochrane Database of Systematic Reviews, MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS, DARE, HTA Database, Campbell database, JBI Database of Systematic Reviews and Implementation Reports, EPPI-Centre Evidence Library. A manual search was also carried out. We included the evidence published up to 1 July 2022. RESULTS: We included the evidence published up to 1 July 2022. We considered 139 RCTs and 1725 NRSI as potentially eligible. Two RCTs (N = 681) comparing CAR-T therapy with SoC in patients with recurrent/relapsed (R/R) B-cell lymphoma were included. RCTs did not show statistical differences in OS, serious adverse events, or total adverse events with grade ⩾ 3. Higher complete response with substantial heterogeneity [risk ratio = 1.59; 95% confidence interval (CI) = (1.30–1.93); I(2) = 89%; 2 studies; 681 participants; very low certainty evidence] and higher progression-free survival [hazard ratio for progression or death = 0.49; 95% CI = (0.37–0.65); 1 study; 359 participants; moderate certainty evidence] were reported with CAR-T therapies. Nine NRSI (N = 540) in patients with T or B-cell acute lymphoblastic leukemia or R/R B-cell lymphoma were also included, providing secondary data. In general, the GRADE certainty of the evidence for main outcomes was mostly low or very low. CONCLUSION: So far, assuming important limitations in the level of certainty due to scarce and heterogenous comparative studies, CAR-T therapies have shown some benefit in terms of progression-free survival, but no overall survival, in patients with R/R B-cell lymphoma. Despite one-arm trials have already facilitated approval of CAR-T cell treatments, additional evidence from large comparative studies is still needed to better characterize the benefit-harm ratio of the use of CAR-T in a variety of patient populations with hematological malignancies. REGISTRATION: https://doi.org/10.12688/openreseurope.14390.1 PROSPERO/OSF PREREGISTRATION: 10.17605/OSF.IO/V6HDX
format Online
Article
Text
id pubmed-10150428
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101504282023-05-02 Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies Saiz, Luis Carlos Leache, Leire Gutiérrez-Valencia, Marta Erviti, Juan Rojas Reyes, María Ximena Ther Adv Hematol Systematic Review BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) cell therapies have been claimed to be curative in responsive patients. Nonetheless, response rates can vary according to different characteristics, and these therapies are associated with important adverse events such as cytokine release syndrome, neurologic adverse events, and B-cell aplasia. OBJECTIVES: This living systematic review aims to provide a timely, rigorous, and continuously updated synthesis of the evidence available on the role of CAR-T therapy for the treatment of patients with hematologic malignancies. DESIGN: A systematic review with meta-analysis of randomized controlled trials (RCTs) and comparative non-randomized studies of interventions (NRSI), evaluating the effect of CAR-T therapy versus other active treatments, hematopoietic stem cell transplantation, standard of care (SoC) or any other intervention, was performed in patients with hematologic malignancies. The primary outcome is overall survival (OS). Certainty of the evidence was determined using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. DATA SOURCES AND METHODS: Searches were performed in the Epistemonikos database, which collates information from multiple sources to identify systematic reviews and their included primary studies, including Cochrane Database of Systematic Reviews, MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS, DARE, HTA Database, Campbell database, JBI Database of Systematic Reviews and Implementation Reports, EPPI-Centre Evidence Library. A manual search was also carried out. We included the evidence published up to 1 July 2022. RESULTS: We included the evidence published up to 1 July 2022. We considered 139 RCTs and 1725 NRSI as potentially eligible. Two RCTs (N = 681) comparing CAR-T therapy with SoC in patients with recurrent/relapsed (R/R) B-cell lymphoma were included. RCTs did not show statistical differences in OS, serious adverse events, or total adverse events with grade ⩾ 3. Higher complete response with substantial heterogeneity [risk ratio = 1.59; 95% confidence interval (CI) = (1.30–1.93); I(2) = 89%; 2 studies; 681 participants; very low certainty evidence] and higher progression-free survival [hazard ratio for progression or death = 0.49; 95% CI = (0.37–0.65); 1 study; 359 participants; moderate certainty evidence] were reported with CAR-T therapies. Nine NRSI (N = 540) in patients with T or B-cell acute lymphoblastic leukemia or R/R B-cell lymphoma were also included, providing secondary data. In general, the GRADE certainty of the evidence for main outcomes was mostly low or very low. CONCLUSION: So far, assuming important limitations in the level of certainty due to scarce and heterogenous comparative studies, CAR-T therapies have shown some benefit in terms of progression-free survival, but no overall survival, in patients with R/R B-cell lymphoma. Despite one-arm trials have already facilitated approval of CAR-T cell treatments, additional evidence from large comparative studies is still needed to better characterize the benefit-harm ratio of the use of CAR-T in a variety of patient populations with hematological malignancies. REGISTRATION: https://doi.org/10.12688/openreseurope.14390.1 PROSPERO/OSF PREREGISTRATION: 10.17605/OSF.IO/V6HDX SAGE Publications 2023-04-27 /pmc/articles/PMC10150428/ /pubmed/37138698 http://dx.doi.org/10.1177/20406207231168211 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Systematic Review
Saiz, Luis Carlos
Leache, Leire
Gutiérrez-Valencia, Marta
Erviti, Juan
Rojas Reyes, María Ximena
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title_full Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title_fullStr Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title_full_unstemmed Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title_short Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
title_sort efficacy and safety of chimeric antigen receptor t-cell (car-t) therapy in hematologic malignancies: a living systematic review on comparative studies
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150428/
https://www.ncbi.nlm.nih.gov/pubmed/37138698
http://dx.doi.org/10.1177/20406207231168211
work_keys_str_mv AT saizluiscarlos efficacyandsafetyofchimericantigenreceptortcellcarttherapyinhematologicmalignanciesalivingsystematicreviewoncomparativestudies
AT leacheleire efficacyandsafetyofchimericantigenreceptortcellcarttherapyinhematologicmalignanciesalivingsystematicreviewoncomparativestudies
AT gutierrezvalenciamarta efficacyandsafetyofchimericantigenreceptortcellcarttherapyinhematologicmalignanciesalivingsystematicreviewoncomparativestudies
AT ervitijuan efficacyandsafetyofchimericantigenreceptortcellcarttherapyinhematologicmalignanciesalivingsystematicreviewoncomparativestudies
AT rojasreyesmariaximena efficacyandsafetyofchimericantigenreceptortcellcarttherapyinhematologicmalignanciesalivingsystematicreviewoncomparativestudies